

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

GRANT OF SHARE OPTIONS

This announcement is made by SciClone Pharmaceuticals (Holdings) Limited (the “**Company**” or “**SciClone**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.06A of the Listing Rules of the Stock Exchange.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that, on December 1, 2023, the Company granted share options (the “**Share Option(s)**”) to certain eligible employees of the Company (the “**Grantees of Share Options**”), under the Post-IPO Option Plan adopted by the Company on January 22, 2021 to subscribe for an aggregate of 394,300 ordinary shares of the Company (the “**Share(s)**”).

Details of the Share Options granted are set out below:

Date of Grant: December 1, 2023 (the “**Date of Grant**”)

Exercise price of the Share Options: HK\$13.40 per Share, representing the highest of:

- a) the closing price of HK\$13.40 per Share as stated in the daily quotation sheets of the Stock Exchange on the Date of Grant;
- b) the average closing price of HK\$13.00 per Share as stated in the daily quotation sheets of the Stock Exchange for the five business days immediately preceding the Date of Grant; and
- c) the nominal value of US\$0.00005 per Share.

Number of Share Options granted:	394,300 Share Options (each Share Option shall entitle the grantee to subscribe for one Share)		
Vesting dates of the Share Options:	Subject to fulfillment of vesting conditions, the Share Options granted to the Grantees of Share Options shall be vested as follows:		
	Number of Share Options	50% Vested On	50% Vested On
	87,800	April 30, 2024	April 30, 2025
	143,400	June 30, 2024	June 30, 2025
	63,300	August 31, 2024	August 31, 2025
	99,800	October 31, 2024	October 31, 2025
Validity period of the Share Options:	Subject to the vesting dates, the Share Options will be valid until November 30, 2033 (the “ Validity Period of the Share Options ”).		

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries: (i) no financial assistance has been provided by the Group to the Grantees of Share Options for the purchase of Shares under the Post-IPO Option Plan; (ii) none of the Grantees of Share Options is a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (iii) none of the Grantees of Share Options is a related entity participant or service provider (as defined under the Listing Rules), and all of the Grantees of Share Options are full time employees of the Group; and (iv) none of the Grantees of Share Options is a participant with options and awards granted and to be granted exceed the 1% individual limit under the Listing Rules.

Vesting Period

The Post-IPO Option Plan provides that the Board may specify the vesting period of the Share Options and does not provide for any minimum vesting period. The Board considers that, taking into account that: (i) the remunerations of the Grantees of Share Options include the grant of share options as part of their package to incentivise their performance and to make continuous contributions to the growth and development of the Group, as well as maintaining the competitiveness of the package offered by the Company as compared with those offered by the industry peers; and (ii) the respective remuneration packages of the Grantees of Share Options are provided according to the internal policy of the Company with reference to their industry experience, tenure and roles with the Group, and contribution to the development and growth of the business of the Group, the grant of Share Options with vesting period less than 12 month to the Grantees of Share Options is appropriate.

Performance Target

The vesting of each tranche of the Share Options as described above is subject to satisfaction of certain performance targets as determined by the Board at its absolute discretion, either on a case-by-case basis or generally:

- 1) Group level performance: The Board will assess the performance of the Group for the relevant period, including in particular key performance indicators, such as the Group's revenue and profit of the Group as a whole and of the applicable business; and
- 2) Individual level performance: The Group has established a standard performance appraisal system for its employees to evaluate their performance and contribution to the Group. The Company will determine whether the Grantees of Share Options meet the individual performance target based on their performance appraisal results for the relevant period.

Clawback Mechanism

A Share Option shall lapse automatically (to the extent not already exercised) on the earliest of:

- (i) the expiry of the period within which a Share Option may be exercised, which is to be determined and notified by the Board to each Grantee of the Share Options at the time of making an offer, and shall not expire later than the Validity Period of the Share Options;
- (ii) the expiry of any of the periods for exercising the Share Option(s); and
- (iii) the date on which the Grantee of the Share Options commits a breach of the rules of the Post-IPO Option Plan.

Reasons and Benefits of the Grant of Share Options

The purpose of the grant of Share Options is to provide incentives and rewards to Grantees of Share Options for their contributions to and continuing efforts to promote the interests of the Company, and the grant of Share Options aligns the interests of the Grantees of Share Options with that of the Company and the shareholders of the Company and reinforces commitment of the Grantees of Share Options to the Group. The Board is of the view that the grant of Share Options will encourage and retain the Grantees of Share Options to make continuous contributions to the growth and development of the Group and is in the interests of the Company and the shareholders of the Company.

Miscellaneous

Subsequent to the grant of Share Options, the number of Shares available for future grant pursuant to the Post-IPO Option Plan is 31,545,536 Shares.

DEFINITIONS

“Listing Rules”	Rules Governing the Listing of securities on The Stock Exchange of Hong Kong Limited
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
*Executive Director, Chief Executive Officer
and President*

Hong Kong, December 1, 2023

As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*